Desperate move or winning formula: BMS to test hep C drug with sovaldi
This article was originally published in Scrip
In an attempt to keep up with the fierce competition surrounding new treatments for hepatitis C virus, Bristol-Myers Squibb is testing its in-house, experimental, antiviral drug combination with Gilead Sciences' market leading product Sovaldi (sofosbuvir) in a 4-week dose regimen trial.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.